Given their essential role in cell cycle progression, CDK4/6 present promising therapeutic targets in BC with three orally-administered CDK4/6 inhibitors, i.e., palbociclib, ribociclib, and abemaciclib, approved by the FDA for the treatment of patients with HR+/HER2- metastatic BC. Here, HR is linked to breast cancer.